[go: up one dir, main page]

PE20020870A1 - 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas - Google Patents

6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas

Info

Publication number
PE20020870A1
PE20020870A1 PE2002000103A PE2002000103A PE20020870A1 PE 20020870 A1 PE20020870 A1 PE 20020870A1 PE 2002000103 A PE2002000103 A PE 2002000103A PE 2002000103 A PE2002000103 A PE 2002000103A PE 20020870 A1 PE20020870 A1 PE 20020870A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
heteroaryl
optionally substituted
tetrahydro
Prior art date
Application number
PE2002000103A
Other languages
English (en)
Inventor
Paulus Wohlfart
Hartmut Strobel
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20020870A1 publication Critical patent/PE20020870A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/54—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/74—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A 6,7,8,9-TETRAHIDRO-5H-BENZOCICLOHEPTENIL-AMINA ACILADA DE FORMULA I DONDE R1 Y R4 SON H, ALQUILO C1-C10, ALQUENILO C2-C10 OPCIONALMENTE SUSTITUIDOS CON F, OH, ALCOXI C1-C8, CN, COOR6, CONR7R8, FENILO, HETEROARILO OPCIONALMENTE SUSTITUIDOS POR HALOGENO, ALQUILO C1-C3, CF3, R9CO, CONR10R11, COOR12, NR13R14, OR15, SOmR16, SO2NR17R18, NO2; R2 Y R3 SON H, HALOGENO, ALQUILO C1-C10; A ES CH2, CHOH, CH-ALQUILO C1-C3; B, C Y D SON CH2, CH-ALQUILO C1-C3; R5 ES Ar, Het Y Ar SON HALOGENO, NH2, ALQUILO C1-C10, ALQUENILO C2-C10, ENTRE OTROS; R6, R12 SON H, ALQUILO C1-C10 OPCIONALMENTE SUSTITUIDO CON F, ALCOXI C1-C8, DIALQUIL C1-C8-AMINO, ENTRE OTROS; R7, R10, R17 SON H, ALQUILO C1-C10 OPCIONALMENTE SUSTITUIDO CON F, ALCOXI C1-C8, FENILO, ENTRE OTROS; R8 Y R11 SON ALQUILO C1-C10 OPCIONALMENTE SUSTITUIDO CON F, ALCOXI C1-C4, FENILO, HETEROARILO; R13 Y R14 SON H, ALQUILO C1-C6, FENILO, BENCILO, HETEROARILO, ENTRE OTROS; R15 ES H, ALQUILO C1-C10, BENCILO, FENILO, HETEROARILO, ENTRE OTROS; R16 ES ALQUILO C1-C10, ARILO ES FENILO, NAFT-1-IL, NAFT-2-IL; m ES 0-2. SON COMPUESTOS PREFERIDOS (6,7,8,9-TETRAHIDRO-5H-BENZOCICLOHEPTEN-6IL)-AMIDA DE ACIDO 2,5-DIMETIL-1-PIRIDIN-4-ILMETIL-1H-PIRROL-3-CARBOXILICO; 6,7,8,9-TETRAHIDRO-5H-BENZOCICLOHEPTEN-6IL)-AMIDA DE ACIDO 5-METIL-1-FENIL-1H-PIRAZOL-4-CARBOXILICO, ENTRE OTROS. LOS COMPUESTOS ELEVAN LA EXPRESION DE eNOS EN CELULAS ENDOTELIALES Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES, ANGINA DE PECHO
PE2002000103A 2001-02-13 2002-02-11 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas PE20020870A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01102853 2001-02-13

Publications (1)

Publication Number Publication Date
PE20020870A1 true PE20020870A1 (es) 2002-11-18

Family

ID=8176424

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000103A PE20020870A1 (es) 2001-02-13 2002-02-11 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas

Country Status (32)

Country Link
US (2) US6759412B2 (es)
EP (1) EP1362027B1 (es)
JP (1) JP4319836B2 (es)
KR (1) KR100975781B1 (es)
CN (1) CN1296346C (es)
AR (1) AR035431A1 (es)
AT (1) ATE396171T1 (es)
AU (1) AU2002253012B2 (es)
BG (1) BG108060A (es)
BR (1) BR0207197A (es)
CA (1) CA2438324C (es)
CZ (1) CZ20032134A3 (es)
DE (1) DE60226704D1 (es)
DK (1) DK1362027T3 (es)
EE (1) EE200300370A (es)
ES (1) ES2304432T3 (es)
HR (1) HRP20030645A2 (es)
HU (1) HUP0303133A3 (es)
IL (2) IL157211A0 (es)
MX (1) MXPA03006893A (es)
MY (1) MY136316A (es)
NO (1) NO328767B1 (es)
NZ (1) NZ527471A (es)
PE (1) PE20020870A1 (es)
PL (1) PL363639A1 (es)
PT (1) PT1362027E (es)
RU (1) RU2301797C2 (es)
SK (1) SK10092003A3 (es)
UY (1) UY27165A1 (es)
WO (1) WO2002064546A2 (es)
YU (1) YU64203A (es)
ZA (1) ZA200305414B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
MY136316A (en) * 2001-02-13 2008-09-30 Sanofi Aventis Deutschland Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
US7176310B1 (en) * 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
US7105513B2 (en) * 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
EP1388342A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7132536B2 (en) * 2003-04-24 2006-11-07 Sanofi-Aventis Deutschland Gmbh Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
KR20060036105A (ko) * 2003-07-29 2006-04-27 제논 파마슈티칼스 인크. 피리딜 유도체 및 그의 치료제로서의 용도
US8309608B2 (en) * 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
EP1529525A1 (en) * 2003-11-06 2005-05-11 Aventis Pharma Deutschland GmbH ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
JP2007277096A (ja) * 2004-07-15 2007-10-25 Astellas Pharma Inc フェネチルニコチンアミド誘導体含有医薬
EP1819341A4 (en) * 2004-11-10 2011-06-29 Synta Pharmaceuticals Corp IL-12 MODULATORY CONNECTIONS
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
EP1741709A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
EP1741708A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
RS54216B1 (sr) 2006-03-22 2015-12-31 F. Hoffmann-La Roche Ag. Pirazoli kao 11-beta-hsd-1
EP1905764A1 (en) 2006-09-30 2008-04-02 Sanofi-Aventis Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals
EP1923062A1 (en) 2006-11-16 2008-05-21 sanofi-aventis Imidazo[2,1-b]thiazoles and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
EP1964840A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
JP5860459B2 (ja) 2010-06-30 2016-02-16 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激薬
ES2572803T3 (es) 2010-11-09 2016-06-02 Ironwood Pharmaceuticals, Inc. Estimuladores de GCs
US20120309796A1 (en) * 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
US9139564B2 (en) 2011-12-27 2015-09-22 Ironwood Pharmaceuticals, Inc. 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2897953B8 (en) 2012-09-19 2019-06-26 Cyclerion Therapeutics, Inc. Sgc stimulators
RS59981B1 (sr) 2013-03-15 2020-03-31 Cyclerion Therapeutics Inc Sgc stimulatori
WO2014197385A1 (en) * 2013-06-03 2014-12-11 Marvin Sackner Passive simulated jogging device
US20160311826A1 (en) 2013-12-11 2016-10-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US20160324856A1 (en) 2014-01-13 2016-11-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of neuromuscular disorders
AU2015317824A1 (en) 2014-09-17 2017-03-23 Cyclerion Therapeutics, Inc. Pyrazole derivatives as sGC stimulators
US10844064B2 (en) 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
KR102513343B1 (ko) 2016-07-07 2023-03-22 사이클리온 테라퓨틱스, 인크. sGC 자극제의 인 전구약물
JP2019524710A (ja) 2016-07-07 2019-09-05 アイアンウッド ファーマシューティカルズ インコーポレイテッド Ｓｇｃ刺激剤の固体形態
CN113924294B (zh) * 2019-05-29 2024-12-06 先正达农作物保护股份公司 杀微生物衍生物
WO2024091983A1 (en) * 2022-10-25 2024-05-02 Artus Therapeutics, Inc. Therapeutic agents for enhancing epithelial and/or endothelial barrier function
CN119409797A (zh) * 2025-01-07 2025-02-11 中肽生化有限公司 一种替度鲁肽的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8402275A (en) * 1974-08-26 1977-02-17 Takeda Chemical Industries Ltd Benzocycloheptene derivatives
CH635310A5 (en) * 1977-05-23 1983-03-31 Sandoz Ag Process for preparing novel benzocycloheptene derivatives
DE3807813A1 (de) 1988-03-10 1989-09-21 Thomae Gmbh Dr K Neue benzocycloheptenderivate, diese verbindungen enthaltende arzneimittel und verfahren zu deren herstellung
SK281442B6 (sk) 1995-08-10 2001-03-12 Astra Aktiebolag Bicyklické amidínové deriváty, spôsob ich prípravy, farmaceutické kompozície s ich obsahom a ich použitie
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
WO2000003746A2 (en) * 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
AUPP891299A0 (en) 1999-02-26 1999-03-25 Fujisawa Pharmaceutical Co., Ltd. New 6-membered cyclic compounds
AUPQ309399A0 (en) 1999-09-28 1999-10-21 Fujisawa Pharmaceutical Co., Ltd. Benzothiazoline derivatives
MY136316A (en) 2001-02-13 2008-09-30 Sanofi Aventis Deutschland Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
TWI241190B (en) 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
PE20020856A1 (es) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
US7186735B2 (en) * 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7338956B2 (en) * 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7105513B2 (en) * 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US8309608B2 (en) * 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases

Also Published As

Publication number Publication date
YU64203A (sh) 2006-05-25
BR0207197A (pt) 2004-07-06
DK1362027T3 (da) 2008-09-22
WO2002064546A3 (en) 2002-11-07
PL363639A1 (en) 2004-11-29
HRP20030645A2 (en) 2005-06-30
CN1296346C (zh) 2007-01-24
CA2438324A1 (en) 2002-08-22
NO20033566D0 (no) 2003-08-12
MXPA03006893A (es) 2004-04-02
UY27165A1 (es) 2002-07-31
US6759412B2 (en) 2004-07-06
WO2002064546A2 (en) 2002-08-22
KR100975781B1 (ko) 2010-08-17
RU2301797C2 (ru) 2007-06-27
JP4319836B2 (ja) 2009-08-26
ES2304432T3 (es) 2008-10-16
NZ527471A (en) 2005-02-25
AR035431A1 (es) 2004-05-26
JP2004518720A (ja) 2004-06-24
US20030008915A1 (en) 2003-01-09
CZ20032134A3 (cs) 2003-10-15
US20040225013A1 (en) 2004-11-11
DE60226704D1 (de) 2008-07-03
ATE396171T1 (de) 2008-06-15
IL157211A (en) 2009-05-04
BG108060A (bg) 2005-01-31
US7709478B2 (en) 2010-05-04
AU2002253012B2 (en) 2008-01-24
PT1362027E (pt) 2008-07-11
EP1362027B1 (en) 2008-05-21
HUP0303133A3 (en) 2007-08-28
IL157211A0 (en) 2004-02-19
NO20033566L (no) 2003-10-13
CN1491208A (zh) 2004-04-21
EE200300370A (et) 2003-10-15
HUP0303133A2 (hu) 2003-12-29
CA2438324C (en) 2009-07-07
NO328767B1 (no) 2010-05-10
RU2003127723A (ru) 2005-03-20
KR20030077619A (ko) 2003-10-01
EP1362027A2 (en) 2003-11-19
HK1061017A1 (en) 2004-09-03
ZA200305414B (en) 2004-05-20
MY136316A (en) 2008-09-30
SK10092003A3 (sk) 2004-01-08

Similar Documents

Publication Publication Date Title
PE20020870A1 (es) 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas
PE20020220A1 (es) Compuestos de nitrilo de dipeptido como inhibidores de catepsina k
PE20000064A1 (es) Compuesto de tiourea y benzamida, composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
PE20050460A1 (es) COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE20051155A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
AR051839A1 (es) Metodo para preparar n-fenilpirazol -1- carboxamidas
MXPA02006317A (es) Nuevos moduladores de neurotransmision de dopamina.
PE20090417A1 (es) Compuestos de piperazina con accion herbicida
PE13396A1 (es) Compuesto biciclico
PE20040898A1 (es) Nuevos compuestos derivados de pirimidina
RU2009149307A (ru) Новое амидное производное для ингибирования роста раковых клеток
PE20081199A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
CA2324418A1 (en) Novel opiate compounds, methods of making and methods of use
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
ES8500271A1 (es) Un procedimiento para preparar nuevas benzamidas y anilidas.
PE20040762A1 (es) Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer
PE20120657A1 (es) Compuesto para el tratamiento de trastornos metabolicos
ATE432926T1 (de) Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung
PE20020253A1 (es) Derivados de 3-azabiciclo[3.1.0]hexano como ligandos de receptores opiaceos
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed